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tumors posing a low risk of malignancy, where‑
as type III neoplasm has a poor prognosis, and 
type IV neoplasm—an extremely poor progno‑
sis with a mean survival time of several months.
We present a case of a 65 ‑year ‑old female kid‑
ney transplant recipient treated with triple im‑
munosuppressive therapy (prednisolone, cyclo‑
sporine, and mycophenolate mofetil), with end‑
‑stage renal disease of her own kidneys due to 
diabetic nephropathy, with hypertension, and 
a history of cytomegalovirus infection, who 
was incidentally diagnosed with asymptomat‑
ic neuroendocrine tumor of the gastric antrum 
25 months after transplant. Routine endosco‑
py was performed and showed the granular, er‑
ythematous pattern of the mucous membrane 
in the antrum (FIGURE 1A and 1B). Features of low‑
‑grade neuroendocrine tumor were found on 
histopathological examination, with a mitotic 
index below 1 mitosis / 10 high ‑power fields, 
and 70% of the section volume was involved, 
with infiltrated margins of the specimen slice. 
Additionally, traits of chronic atrophic gastri‑
tis with intestinal metaplasia were detected 
(FIGURE 1C and 1D). The patient denied having 
any symptoms.
Neuroendocrine neoplasms are rare tumors 
(2.89 to 6.98 cases per 100 000 people per year 
in the United States)1,2 originating from neuro‑
endocrine cells (neural crest, neuroendocrine is‑
lets, and stem cells), with a rising incidence dur‑
ing several past decades. This type of tumors can 
be benign or malignant and may develop in var‑
ious organs, particularly in the gastrointestinal 
and pulmonary systems.
One of their subtypes, gastric neuroendocrine 
tumors, account for 1 to 2 cases per 1 million per‑
sons per year and represent 8.7% of all gastroin‑
testinal neuroendocrine tumors.3,4
They originate from enterochromaffin ‑like 
cells of the gastric mucosa or, less commonly, 
from other types of endocrine cells (that se‑
crete serotonin, gastrin, or adrenocorticotrop‑
ic hormone).4 Patients may develop symptoms 
of uncontrolled hormone secretion or caused by 
tumor invasion.
Prognosis and survival depend on the type 
of tumor. There is a classification distinguish‑
ing 4 tumor types, based on their histological 
and morphological characteristics and patho‑
genesis.4 Well ‑differentiated type I and II gastric 
neuroendocrine neoplasms are mostly benign 
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Previous endoscopy (performed 15 months ear‑
lier) demonstrated only erosive gastritis in the an‑
trum and polyps in the stomach body.
After establishing the diagnosis, a modifica‑
tion of the immunosuppressive therapy was rec‑
ommended, ie, a switch from the calcineurin in‑
hibitor to an mTOR inhibitor, but the patient dis‑
agreed with the suggestion and the previous ther‑
apy was therefore continued.
Concurrently, the  patient was referred to 
the endocrinology outpatient clinic. She under‑
went 99mtechnetium sestamibi single ‑photon 
emission computed tomography of the abdo‑
men and pelvis. No remarkable tracer concen‑
tration or increased tracer uptake were revealed. 
The case was discussed during a tumor board con‑
ference and a decision was made to closely mon‑
itor the patient.
Recent gastroscopy, performed 6 months af‑
ter endoscopic tumor removal, showed signs of 
inactive chronic gastritis with foveolar hyperpla‑
sia in the antrum. No other abnormalities were 
detected.
This case is an interesting example of a very 
rare neoplasm developing in transplant recipi‑
ents who are at increased risk of malignancies, 
but typically develop skin and renal malignancies 
or lymphomas. There are several cases of post‑
transplant neuroendocrine neoplasms, including 
mainly Merkel cell carcinoma or a single case of 
rectal neuroendocrine neoplasm.5 The presented 
case indicates the importance of accurate cancer 
screening in patients after organ transplants, as 
early detection makes it possible to implement 
proper treatment quickly—in this case, it was 
endoscopic tumor removal. In our clinical cen‑
ter, kidney transplant recipients have obligatory 
gastroscopy performed once a year and colonos‑
copy every 2 years or once a year in those with 
colon polyps. Close follow ‑up after cancer diag‑
nosis is also crucial. However, the appropriate 
management of neuroendocrine neoplasms re‑
mains a challenge, as there are only scarce data 
available on this issue.
FIGURE 1 C – hematoxylin ‑eosin staining, magnification × 400: tumor cells forming cohesive nests (arrows). 
The nuclei are round or oval in shape and rather uniform, with finely dispersed chromatin. D – hematoxylin ‑eosin 
staining, magnification × 400: the lamina propria infiltrated by rather uniform neuroendocrine cells (arrows)
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